Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Fulcrum Therapeutics (FULC) EPS (Basic): 2019-2024

Historic EPS (Basic) for Fulcrum Therapeutics (FULC) over the last 6 years, with Dec 2024 value amounting to -$0.16.

  • Fulcrum Therapeutics' EPS (Basic) rose 11.43% to -$0.31 in Q3 2025 from the same period last year, while for Sep 2025 it was -$1.21, marking a year-over-year decrease of 317.24%. This contributed to the annual value of -$0.16 for FY2024, which is 89.94% up from last year.
  • According to the latest figures from FY2024, Fulcrum Therapeutics' EPS (Basic) is -$0.16, which was up 89.94% from -$1.59 recorded in FY2023.
  • Fulcrum Therapeutics' EPS (Basic)'s 5-year high stood at -$0.16 during FY2024, with a 5-year trough of -$2.79 in FY2020.
  • For the 3-year period, Fulcrum Therapeutics' EPS (Basic) averaged around -$1.40, with its median value being -$1.59 (2023).
  • As far as peak fluctuations go, Fulcrum Therapeutics' EPS (Basic) declined by 6.55% in 2022, and later surged by 89.94% in 2024.
  • Over the past 5 years, Fulcrum Therapeutics' EPS (Basic) (Yearly) stood at -$2.79 in 2020, then rose by 17.92% to -$2.29 in 2021, then fell by 6.55% to -$2.44 in 2022, then soared by 34.84% to -$1.59 in 2023, then spiked by 89.94% to -$0.16 in 2024.